[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2536742T3 - Leczenie zaburzeń żołądkowo-jelitowych - Google Patents

Leczenie zaburzeń żołądkowo-jelitowych

Info

Publication number
PL2536742T3
PL2536742T3 PL11706694T PL11706694T PL2536742T3 PL 2536742 T3 PL2536742 T3 PL 2536742T3 PL 11706694 T PL11706694 T PL 11706694T PL 11706694 T PL11706694 T PL 11706694T PL 2536742 T3 PL2536742 T3 PL 2536742T3
Authority
PL
Poland
Prior art keywords
treatments
gastrointestinal disorders
gastrointestinal
disorders
Prior art date
Application number
PL11706694T
Other languages
English (en)
Inventor
Angelika Fretzen
Hong Zhao
Marco Kessler
Original Assignee
Ironwood Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2536742(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals, Inc. filed Critical Ironwood Pharmaceuticals, Inc.
Publication of PL2536742T3 publication Critical patent/PL2536742T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11706694T 2010-02-17 2011-02-17 Leczenie zaburzeń żołądkowo-jelitowych PL2536742T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30546510P 2010-02-17 2010-02-17
EP11706694.4A EP2536742B1 (en) 2010-02-17 2011-02-17 Treatments for gastrointestinal disorders

Publications (1)

Publication Number Publication Date
PL2536742T3 true PL2536742T3 (pl) 2017-11-30

Family

ID=43875305

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11706694T PL2536742T3 (pl) 2010-02-17 2011-02-17 Leczenie zaburzeń żołądkowo-jelitowych

Country Status (13)

Country Link
US (6) US8933030B2 (pl)
EP (1) EP2536742B1 (pl)
CN (1) CN102869677B (pl)
AU (3) AU2011218009B2 (pl)
CA (1) CA2790213A1 (pl)
DK (1) DK2536742T3 (pl)
EA (1) EA201290799A1 (pl)
ES (1) ES2638589T3 (pl)
MX (1) MX340234B (pl)
PL (1) PL2536742T3 (pl)
TR (1) TR201711271T4 (pl)
UA (1) UA108636C2 (pl)
WO (1) WO2011103311A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811001A1 (en) * 2010-09-11 2012-03-15 Ironwood Pharmaceuticals, Inc. Treatment of constipation-predominant irritable bowel syndrome
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
CN104231051B (zh) * 2013-06-06 2020-06-26 深圳翰宇药业股份有限公司 一种利那洛肽的制备方法
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2015166468A1 (en) * 2014-05-02 2015-11-05 Sinoveda Canada, Inc. Formulas comprising highly soluble elements and vitamin d for the prevention and treatment of bowel conditions during calcium supplementation
KR20180005675A (ko) * 2015-05-01 2018-01-16 아이언우드 파마슈티컬스, 인코포레이티드 결장 세정을 위한 조성물 및 위장 장애의 치료
WO2018119191A1 (en) 2016-12-21 2018-06-28 Ironwood Pharmaceuticals Inc. Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
CN106831950A (zh) * 2017-03-18 2017-06-13 南京工业大学 一种制备利那洛肽的方法
IT201700054380A1 (it) * 2017-05-19 2018-11-19 Aboca Spa Societa Agricola Composizioni contenenti sistemi di rilascio di anidride carbonica ottenuti da succhi vegetali
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
JPH03505334A (ja) 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5654278A (en) 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
IL127769A (en) 1996-07-03 2006-10-31 Alza Corp Non-aqueous protic preparations of peptides
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
EP1098636A1 (en) 1998-07-23 2001-05-16 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
ATE279914T1 (de) 1998-11-27 2004-11-15 Kanji Takada Oral anzuwendendes arzneimittel zur wirkstoffverabreichung im magendarmtrakt
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
KR20080064908A (ko) 2000-06-28 2008-07-09 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002026248A1 (en) 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
AU2002241723A1 (en) 2000-12-21 2002-07-24 Inhale Therapeutic Systems, Inc. Storage stable powder compositions of interleukin-4 receptor
JP2004521123A (ja) 2001-02-02 2004-07-15 ファルマシア・コーポレーション 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ
GB0104371D0 (en) 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
PT1379224E (pt) 2001-03-29 2009-10-22 Synergy Pharmaceuticals Inc Agonistas do receptor da guanilato ciclase para o tratamento de inflamação de tecidos e carcinogénese
WO2003014304A2 (en) 2001-08-09 2003-02-20 Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International Protonic formulation
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
CN1606452A (zh) 2001-12-21 2005-04-13 诺沃娜第克公司 修饰的因子ⅶ多肽的液体组合物
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
NZ539915A (en) 2002-12-11 2007-09-28 Pfizer Prod Inc Controlled-release of an active substance into a high fat environment
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1594517B1 (en) 2003-01-28 2007-06-20 Microbia, Inc. Compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004012745T2 (de) 2003-05-14 2009-04-09 Indus Biotech Pvt. Ltd. Synergistische zusammensetzung zur behandlung von diabetes mellitus
EA009676B1 (ru) 2003-06-10 2008-02-28 Эл Джи Лайф Сайенсиз Лтд. Водный препарат эритропоэтина человека
WO2005016244A2 (en) 2003-06-13 2005-02-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE202004020676U1 (de) 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
JP4744533B2 (ja) 2004-12-30 2011-08-10 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
WO2007022531A2 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
WO2007101161A2 (en) 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
EP2078529B1 (en) 2006-07-10 2014-12-10 PBA3 Biomed GmbH Antimicrobial peptides
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
JP5042312B2 (ja) 2006-08-31 2012-10-03 ノバルティス アーゲー Ｈｇｈを含む経口送達用医薬組成物
CA2673260A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
CN109010254A (zh) * 2008-08-15 2018-12-18 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
US20120009225A1 (en) 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2770334A1 (en) 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide
DK2521561T3 (en) 2009-11-03 2017-09-11 Ironwood Pharmaceuticals Inc LINACLOTID FOR TREATMENT OF CHRONIC CONSTIPATION

Also Published As

Publication number Publication date
EP2536742B1 (en) 2017-07-19
CN102869677B (zh) 2015-07-08
US20220227812A1 (en) 2022-07-21
US20210388026A1 (en) 2021-12-16
DK2536742T3 (en) 2017-09-04
TR201711271T4 (tr) 2019-02-21
CN102869677A (zh) 2013-01-09
US20230340025A1 (en) 2023-10-26
US8933030B2 (en) 2015-01-13
US20200283479A1 (en) 2020-09-10
AU2011218009B2 (en) 2016-11-03
US20130190238A1 (en) 2013-07-25
US20140073571A9 (en) 2014-03-13
AU2011218009A1 (en) 2012-09-13
CA2790213A1 (en) 2011-08-25
AU2019202052A1 (en) 2019-04-18
EA201290799A1 (ru) 2013-03-29
WO2011103311A3 (en) 2011-12-29
US20150094265A1 (en) 2015-04-02
WO2011103311A2 (en) 2011-08-25
AU2017200588A1 (en) 2017-02-23
MX2012009597A (es) 2012-09-28
MX340234B (es) 2016-07-01
ES2638589T3 (es) 2017-10-23
EP2536742A2 (en) 2012-12-26
UA108636C2 (xx) 2015-05-25

Similar Documents

Publication Publication Date Title
ZA201203342B (en) Treatments for gastrointestinal disorders
GB2493100B (en) Combination photodynamic devices
PL2652193T3 (pl) Obróbka
EP2611496A4 (en) Methods of Treatment
IL222481A0 (en) Combination therapy
PL2536742T3 (pl) Leczenie zaburzeń żołądkowo-jelitowych
EP2609848A4 (en) Borescope
EP2668887A4 (en) ENDOSCOPE
EP2666401A4 (en) ENDOSCOPE
EP2552323A4 (en) COMBINATION THERAPY
PT2621569T (pt) Dispositivo de tratamento
EP2599430A4 (en) ENDOSCOPE
EP2698093A4 (en) ENDOSCOPE
EP2671499A4 (en) ENDOSCOPE
EP2638841A4 (en) Borescope
PL2776055T3 (pl) Sposoby leczenia zaburzeń żołądkowo-jelitowych
EP2702923A4 (en) ENDOSCOPE
EP2700348A4 (en) Borescope
EP2581030A4 (en) ENDOSCOPE DEVICE
EP2628434A4 (en) ENDOSCOPE
EP2668892A4 (en) ENDOSCOPE
EP2521569A4 (en) COMBINATION THERAPY WITH VB-201
EP2716203A4 (en) Borescope
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
EP2659828A4 (en) Borescope